AAB Therapeutics

Research news

Latest updates from AAB Therapeutics

#genesis2025 #aabtherapeutics #biotech #drugdiscovery #precisionmedicine #rnatherapeutics #london | AAB TherapeuticsDr. Eline Koers, CEO of AAB Therapeutics, is speaking TODAY at the GENESIS conference in London! 🇬🇧 Eline will be presenting our genetically programmable Extracellular Vesicles (EVs) platform to create next-generation precision biological drugs, delivering therapeutic RNA payloads directly to cancer cells. Let's connect and discuss the future of targeted therapeutics. #GENESIS2025 #AABTherapeutics #Biotech #DrugDiscovery #PrecisionMedicine #RNAtherapeutics #London

🎭 Great to share the stage with Dmitry Veprintsev 🇬🇧 🇨🇭 and Eline Koers from AAB Therapeutics at the Precision EV Forum in Cambridge today to discuss bottlenecks in translation of academic… | Jenny Hirst🎭 Great to share the stage with Dmitry Veprintsev 🇬🇧 🇨🇭 and Eline Koers from AAB Therapeutics at the Precision EV Forum in Cambridge today to discuss bottlenecks in translation of academic research using extracellular vesicles into impact. Unsurprisingly, the lack of funding was high up on the agenda. 🚀 AAB Therapeutics joined Accelerate@Babraham this year, and are benefitting from the support offered at Babraham Research Campus through our accelerator programme and bio-incubator, LiveLabs. It was great to hear Dmitry describe AAB Therapeutics' experience of the support that they have received as "life changing". ❤️ Personally, it was great to hear about the progress in understanding extracellular vesicles and their potential therapeutic and diagnostic applications. Having studied endosomes and lysosomes for >25 years in my academic life, this topic is close to my heart. Thank you to the organisers for the opportunity to present.

I am honoured to contribute AAB Therapeutics perspective on engineered extracellular vesicles as a targeted drug-delivery platform. Looking forward to a stimulating discussion tomorrow! Many thanks… | Dmitry Veprintsev 🇬🇧 🇨🇭I am honoured to contribute AAB Therapeutics perspective on engineered extracellular vesicles as a targeted drug-delivery platform. Looking forward to a stimulating discussion tomorrow! Many thanks to Graham Combe for organising this event.

Page updated

Report abuse